Handgrip weakness, systemic inflammation indicators, and overall survival in lung cancer patients with well performance status: A large multicenter observational study.

Abstract

BACKGROUND:

Systemic inflammation and handgrip weakness have been used to predict mortality in many cancers. The purpose of current study was to evaluate the association of co-occurrence of inflammation indicators and handgrip weakness with overall survival (OS) of lung cancer (LC) patients with good performance status.

METHODS:

The cutoff points for handgrip strength (HGS) and the four inflammation indicators were calculated using Maxstat. The time-dependent receiver operating characteristic curve and C-index were used to select optimal inflammation indicator for predicting OS of LC patients. The Cox proportional hazard regression model was used to calculate the hazard ratio (HR) of mortality. Kaplan-Meier curves were constructed to evaluate the association of indicators and the OS of LC patients.

RESULTS:

Among the 1951 patients, the mean ± standard deviation (SD) age was 60.6 ± 9.9 years, and 1300 (66.6%) patients were male. In patients with good performance status (PS), handgrip weakness (HR, 1.49; 95% confidence interval [95% CI], 1.30-1.70, p < 0.001) and low advanced lung cancer inflammation index (ALI) (HR, 2.05; 95%CI, 1.79-2.34, p < 0.001), high systemic immune-inflammation index (SII) (HR, 1.91; 95%CI, 1.66-2.19, p < 0.001), high platelet: lymphocyte ratio (PLR) (HR, 1.60; 95%CI, 1.40-1.82, p < 0.001), or high neutrophil: lymphocyte ratio (NLR) (HR, 2.01; 95%CI, 1.76-2.30, p < 0.001) were associated with increased mortality risk of LC patients. ALI had better C-index (0.624) and time-AUC in the prediction of OS in LC patients with good PS than other three combinations. The co-occurrence of handgrip weakness and low ALI more than doubled the risk of death in LC with good PS (HR, 2.44; 95% CI, 2.06-2.89, p < 0.001).

CONCLUSION:

In LC patients who have good PS, patients with combined handgrip weakness and low ALI have the worst prognosis.

THE TRIAL REGISTRATION NUMBER:

ChiCTR1800020329.

• Authors: Mengmeng Song, Qi Zhang, Chunhua Song, Tong Liu, Xi Zhang, Guotian Ruan, Meng Tang, Xiaowei Zhang, Hailun Xie, Heyang Zhang, Yizhong Ge, Xiangrui Li, Kangping Zhang, Ming Yang, Qinqin Li, Xiaoyue Liu, Shiqi Lin, Yu Xu, Bo Li, Xiaogang Li, Kunhua Wang, Hongxia Xu, Wei Li, Hanping Shi
• Journal: Cancer medicine (Cancer Med) Vol. 12 Issue 3 Pg. 2818-2830 (02 2023) ISSN: 2045-7634 [Electronic] United States
• PMID: 36073671 (Publication Type: Observational Study, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Topics

• Humans
• Male
• Middle Aged
• Aged
• Female
• Hand Strength
• Lung Neoplasms
• Prognosis
• Lymphocytes
• Neutrophils
• Frailty
• Inflammation
• Retrospective Studies